Coronavirus 2019-2020 thread (no unsubstantiated rumours!)

shanlung

Junior Member
Registered Member
Then what about Trump for not bothering to read memo written in January?
And his entire cabinet for not bothering to read that memo either?

There are still a lot of people who deny the dangerousness of Covid-19. I think the memo had been read, but was misjudged and rejected. To say that they did not read the memo is a lie.

That D removed and sacked the only man with brains from his Cabinet, Jim Mattis.
And got a bunch of dwarves just like himself inside there so he can stand tall.
They were laughing and gloating too much at what happening in China and thinking how to take even greater advantages such as increasing their FONOPs and cutting Huawei and more to pieces.

If Mattis was there, he would not have allowed those memos to be ignored and not acted on.
Instead of the situation now blaming to the right and to the left and to the top and bottom and China , China , China fault.

And by the way, at around midnight 10 April Singapore time, USA gotten SIX China within her border.
And the numbers still rising and rising.
The chances of getting struck by lightning in USA against covid 19 rapidly declining by the day , and in time, by the hour.


Capture.JPG
 

Hendrik_2000

Lieutenant General
Some good news
Two thirds of severe COVID-19 cases improve with remdesivir: NEJM
Updated 11:52, 11-Apr-2020
CGTN
Share
Please, Log in or Register to view URLs content!

b1755ff7a153410ebcb75cc5a9b2195a.jpg

More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences, according to new data based on patient observation.
The analysis, published on Friday by the New England Journal of Medicine (NEJM), does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included – in one case because of a dosing error.

The paper's author called the findings "hopeful," but cautioned that it is difficult to interpret the results since they do not include comparison to a control group, as would be the case in a randomized clinical trial. In addition, the patient numbers were small, the details being disclosed are limited, and the follow-up time was relatively short.
There are currently no approved treatments or preventive vaccines for COVID-19, the respiratory illness caused by the novel coronavirus that has killed more than 100,000 people worldwide.

Gilead last month sharply limited its compassionate use program for remdesivir and is conducting its own clinical trials of the antiviral drug, with results expected in coming weeks. Researchers in China as well as the U.S. National Institutes of Health are also testing the drug in COVID-19 patients.
The new analysis includes patients in the United States, Europe, Canada and Japan who received a 10-day course of intravenous remdesivir.

Before the treatment, 30 patients were on mechanical ventilators, and four were on a machine that pumps blood from the patient's body through an artificial oxygenator. After a median follow-up of 18 days, 36 patients, or 68 percent, had an improvement in oxygen-support class, including more than half of the 30 patients receiving mechanical ventilation who had their breathing tubes removed. A total of 25 patients, or 47 percent, were discharged from the hospital. Seven patients, 13 percent of the total, died.

Twelve patients, 23 percent, had serious side effects including multiple-organ-dysfunction syndrome, septic shock and acute kidney injury.

"We look forward to the results of controlled clinical trials to potentially validate these findings," wrote Dr. Jonathan Grein, the paper's lead author and director of hospital epidemiology at Cedars-Sinai Medical Center, Los Angeles.
(Cover image via Reuters)
Source(s): Reuters
 
Last edited:

supercat

Major
Some good news
Two thirds of severe COVID-19 cases improve with remdesivir: NEJM
Updated 11:52, 11-Apr-2020
CGTN
Share
Please, Log in or Register to view URLs content!


More than two-thirds of severely ill COVID-19 patients saw their condition improve after treatment with remdesivir, an experimental drug being developed by Gilead Sciences, according to new data based on patient observation.
The analysis, published on Friday by the New England Journal of Medicine (NEJM), does not detail what other treatments the 61 hospitalized patients were given and data on eight of them were not included – in one case because of a dosing error.
...

China's experience in treating COVID-19 patients indicates that Kaletra may also have potential. The efficacy of chloroquine is inconclusive, though.
A study published last month in the New England Journal of Medicine, based on a test on severe coronavirus cases at Jinyintan, concluded that Kaletra wasn’t effective. But Jinyintan’s Dr. Zhang said supplementary data in the study suggested it had potential.

Many of the cases at Jinyintan took Kaletra in conjunction with bismuth subcitrate potassium, which had also been effective, he said. Bismuth subcitrate is used in combination with other drugs to treat a common bacterial stomach infection.

Please, Log in or Register to view URLs content!

Situation in the New York metro area:

Cases:94,409
Total hospitalized*:25,920
NYC confirmed deaths:5,429
As of:April 10, 5 p.m.
*Estimated.

1586577193259.jpeg

Situation in the U.S. on April 10 at 8:00 pm EDT:
1586577269189.jpeg

Please, Log in or Register to view URLs content!

Please, Log in or Register to view URLs content!

Please, Log in or Register to view URLs content!

1586577365220.jpeg

Please, Log in or Register to view URLs content!

On April 10, excluding Hong Kong, Macau, and Taiwan, there are 42 imported new cases and 4 domestics new cases. Again, there is a possible small cluster of 3 new cases from Guangdong. There are 34 new asymptomatic cases. There are 8 new suspected cases, all imported. There are 3 deaths nationwide. There are 77,525 cured cases and 1,089 existing cases. Existing cases in Hong Kong and Macau remain unchanged at 711.

1586577753936.jpeg

1586577779768.jpeg

1586577797560.jpeg

Please, Log in or Register to view URLs content!
 
Last edited:

Hendrik_2000

Lieutenant General
The Chinese recombinant vaccine, developed by CanSino Bio and the Military Academy of Medical Sciences, will enter Phase 2 clinical trials with 500 volunteers.
250 will receive an average dose of 1ml,
125 with a low dose of 0.5ml, and
125 with a placebo.
 

Hendrik_2000

Lieutenant General
It is crazy out there for procurement agent
Please, Log in or Register to view URLs content!
Coronavirus crisis makes unlikely heroes: State procurement officials scrambling for supplies — and hoping not to get scammed
Please, Log in or Register to view URLs content!
Senior Political Correspondent
Please, Log in or Register to view URLs content!
April 10, 2020, 5:24 PM UTC



WASHINGTON — Danny Mays has a phrase for the way things used to be, before thousands of Americans started
Please, Log in or Register to view URLs content!
from COVID-19 and everyone else stayed in their homes: blue-sky days.
Mays, 36, is the director of procurement for the state of Maryland. Until a month ago, that job meant he was making deals for the state on everything from construction jobs to software and technology. But now it’s all medical equipment, all the time.

Mays’s job has shifted into overdrive, as he and the 38 people who report to him have scrambled to compete with other states and countries in a mad dash to obtain medical supplies: N95 respirators, surgical masks, gloves and gowns, ventilators and face masks.

In an hourlong interview, Mays described days that start at 7 a.m. with the first of several conference calls, and stretch late into the night as he and others try to nail down deals with suppliers for products that are mostly manufactured in China. The U.S. imports
Please, Log in or Register to view URLs content!
. The 12-hour time difference means a lot of his most important work starts in the evening. “There is no 9-to-5 anymore.”
“In blue-sky days the state doesn’t prepay for anything,” Mays said. “In China right now to secure orders, we’re seeing 50 percent or more deposits required to secure these orders. If you don’t get into that space and compete in that space, then New York is going to get the items or Florida is going to or someone is.”

Costs are skyrocketing. “Pricing on ventilators is through the roof,” Mays said. They’ve gone from $18,000 each to $50,000 a pop. In a normal year, a blue-sky year, Mays said his office will spend about $1 billion on all the contracts he executes. He said it will spend that much, easily, just on the coronavirus crisis.

daae24a0-7b4f-11ea-bd3c-679e9b07e9b5

His office has to field a flood of inquiries from would-be middlemen without experience in medical supplies, seeking to cash in on the bonanza — or just to keep their businesses alive.

“We’re getting hundreds of vendors hitting us up every hour telling us they can sell us what we need, and we know that’s not true given how volatile the supply chain is,” Mays said. “Event management companies … now they’re going to their suppliers that usually make touring equipment and scaffolding and saying, ‘Do you have any suppliers who make N95 masks?’”
 

manqiangrexue

Brigadier
The Chinese recombinant vaccine, developed by CanSino Bio and the Military Academy of Medical Sciences, will enter Phase 2 clinical trials with 500 volunteers.
250 will receive an average dose of 1ml,
125 with a low dose of 0.5ml, and
125 with a placebo.
Who the hell is going to volunteer for the placebo group? That means getting infected by COVID-19 after being injected with saline! LOL That's gotta be a joke; these are people, not mice.
 
Who the hell is going to volunteer for the placebo group? That means getting infected by COVID-19 after being injected with saline! LOL That's gotta be a joke; these are people, not mice.
LOL, after I had noticed that post by Hen.2k, I was thinking if placebo is really needed in COVID-19 case


Hen.2k what's your source 25 minutes ago
The Chinese recombinant vaccine, developed by CanSino Bio and the Military Academy of Medical Sciences, will enter Phase 2 clinical trials with 500 volunteers.
250 will receive an average dose of 1ml,
125 with a low dose of 0.5ml, and
125 with a placebo.
 

localizer

Colonel
Registered Member
Who the hell is going to volunteer for the placebo group? That means getting infected by COVID-19 after being injected with saline! LOL That's gotta be a joke; these are people, not mice.

? It’s a vaccine, they just check for antibodies after. No one is going to get infected with actual covid.

After the trial they can then move to active areas and see if it actually prevents disease.
 
Top